BCL6 overexpression is associated with decreased p19ARF expression and confers an independent prognosticator in gallbladder carcinoma

Peir In Liang, Chien Feng Li, Li Tzong Chen, Ding Ping Sun, Tzu Ju Chen, Chung Hsi Hsing, Han Ping Hsu, Ching Yih Lin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

B cell lymphoma 6 (BCL6) is a protein that is vital for lymphogenesis. Its expression has been well established in lymphoma, especially in diffuse large B-cell lymphoma. Its role in carcinogenesis is less well understood. Previous study shows that BCL6 expression may regulate p19 functions, an important regulator for the p53 pathway. No prior study has attempted to evaluate the significance of BCL6 and p19ARF expression in a large cohort of patients with gallbladder carcinomas (GBCs). We selected 164 patients with GBC and performed immunostains for BCL6 and p19ARF. BCL6 expression and p19ARF expression were evaluated using a histochemical score (H-score). We then correlated the results with various clinicopathological factors, disease-specific survival (DSS), and disease-free survival (DFS). BCL6 overexpression was significantly associated with high pT status, high TNM stage, higher histological grade (p=0.029), vascular invasion, perineurial invasion, high Ki-67 labeling index, and low p19 expression. Importantly, BCL6 overexpression in GBC was strongly associated with worse DSS (pARF expression was correlated with a poor DSS (p=0.0144) and DFS (p=0.0032) in the univariate analysis but was not prognosticatory in the multivariate analysis. In GBC, BCL6 overexpression correlated with adverse phenotypes and decreased p19ARF expression. BCL6 overexpression also independently predicts worse DSS and DFS, suggesting it has a role in tumorigenesis or carcinogenesis and could be a potential prognostic indicator in GBC.

Original languageEnglish
Pages (from-to)1417-1426
Number of pages10
JournalTumor Biology
Volume35
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

B-Cell Lymphoma
Gallbladder
Carcinoma
Disease-Free Survival
Carcinogenesis
Survival
Lymphoma, Large B-Cell, Diffuse
Blood Vessels
Lymphoma
Multivariate Analysis
Phenotype

Keywords

  • BCL6
  • Gallbladder carcinoma
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research

Cite this

BCL6 overexpression is associated with decreased p19ARF expression and confers an independent prognosticator in gallbladder carcinoma. / Liang, Peir In; Li, Chien Feng; Chen, Li Tzong; Sun, Ding Ping; Chen, Tzu Ju; Hsing, Chung Hsi; Hsu, Han Ping; Lin, Ching Yih.

In: Tumor Biology, Vol. 35, No. 2, 2014, p. 1417-1426.

Research output: Contribution to journalArticle

Liang, Peir In ; Li, Chien Feng ; Chen, Li Tzong ; Sun, Ding Ping ; Chen, Tzu Ju ; Hsing, Chung Hsi ; Hsu, Han Ping ; Lin, Ching Yih. / BCL6 overexpression is associated with decreased p19ARF expression and confers an independent prognosticator in gallbladder carcinoma. In: Tumor Biology. 2014 ; Vol. 35, No. 2. pp. 1417-1426.
@article{421d3acf42354dd3a5cc1e4e76e31a6c,
title = "BCL6 overexpression is associated with decreased p19ARF expression and confers an independent prognosticator in gallbladder carcinoma",
abstract = "B cell lymphoma 6 (BCL6) is a protein that is vital for lymphogenesis. Its expression has been well established in lymphoma, especially in diffuse large B-cell lymphoma. Its role in carcinogenesis is less well understood. Previous study shows that BCL6 expression may regulate p19 functions, an important regulator for the p53 pathway. No prior study has attempted to evaluate the significance of BCL6 and p19ARF expression in a large cohort of patients with gallbladder carcinomas (GBCs). We selected 164 patients with GBC and performed immunostains for BCL6 and p19ARF. BCL6 expression and p19ARF expression were evaluated using a histochemical score (H-score). We then correlated the results with various clinicopathological factors, disease-specific survival (DSS), and disease-free survival (DFS). BCL6 overexpression was significantly associated with high pT status, high TNM stage, higher histological grade (p=0.029), vascular invasion, perineurial invasion, high Ki-67 labeling index, and low p19 expression. Importantly, BCL6 overexpression in GBC was strongly associated with worse DSS (pARF expression was correlated with a poor DSS (p=0.0144) and DFS (p=0.0032) in the univariate analysis but was not prognosticatory in the multivariate analysis. In GBC, BCL6 overexpression correlated with adverse phenotypes and decreased p19ARF expression. BCL6 overexpression also independently predicts worse DSS and DFS, suggesting it has a role in tumorigenesis or carcinogenesis and could be a potential prognostic indicator in GBC.",
keywords = "BCL6, Gallbladder carcinoma, Prognosis",
author = "Liang, {Peir In} and Li, {Chien Feng} and Chen, {Li Tzong} and Sun, {Ding Ping} and Chen, {Tzu Ju} and Hsing, {Chung Hsi} and Hsu, {Han Ping} and Lin, {Ching Yih}",
year = "2014",
doi = "10.1007/s13277-013-1195-z",
language = "English",
volume = "35",
pages = "1417--1426",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - BCL6 overexpression is associated with decreased p19ARF expression and confers an independent prognosticator in gallbladder carcinoma

AU - Liang, Peir In

AU - Li, Chien Feng

AU - Chen, Li Tzong

AU - Sun, Ding Ping

AU - Chen, Tzu Ju

AU - Hsing, Chung Hsi

AU - Hsu, Han Ping

AU - Lin, Ching Yih

PY - 2014

Y1 - 2014

N2 - B cell lymphoma 6 (BCL6) is a protein that is vital for lymphogenesis. Its expression has been well established in lymphoma, especially in diffuse large B-cell lymphoma. Its role in carcinogenesis is less well understood. Previous study shows that BCL6 expression may regulate p19 functions, an important regulator for the p53 pathway. No prior study has attempted to evaluate the significance of BCL6 and p19ARF expression in a large cohort of patients with gallbladder carcinomas (GBCs). We selected 164 patients with GBC and performed immunostains for BCL6 and p19ARF. BCL6 expression and p19ARF expression were evaluated using a histochemical score (H-score). We then correlated the results with various clinicopathological factors, disease-specific survival (DSS), and disease-free survival (DFS). BCL6 overexpression was significantly associated with high pT status, high TNM stage, higher histological grade (p=0.029), vascular invasion, perineurial invasion, high Ki-67 labeling index, and low p19 expression. Importantly, BCL6 overexpression in GBC was strongly associated with worse DSS (pARF expression was correlated with a poor DSS (p=0.0144) and DFS (p=0.0032) in the univariate analysis but was not prognosticatory in the multivariate analysis. In GBC, BCL6 overexpression correlated with adverse phenotypes and decreased p19ARF expression. BCL6 overexpression also independently predicts worse DSS and DFS, suggesting it has a role in tumorigenesis or carcinogenesis and could be a potential prognostic indicator in GBC.

AB - B cell lymphoma 6 (BCL6) is a protein that is vital for lymphogenesis. Its expression has been well established in lymphoma, especially in diffuse large B-cell lymphoma. Its role in carcinogenesis is less well understood. Previous study shows that BCL6 expression may regulate p19 functions, an important regulator for the p53 pathway. No prior study has attempted to evaluate the significance of BCL6 and p19ARF expression in a large cohort of patients with gallbladder carcinomas (GBCs). We selected 164 patients with GBC and performed immunostains for BCL6 and p19ARF. BCL6 expression and p19ARF expression were evaluated using a histochemical score (H-score). We then correlated the results with various clinicopathological factors, disease-specific survival (DSS), and disease-free survival (DFS). BCL6 overexpression was significantly associated with high pT status, high TNM stage, higher histological grade (p=0.029), vascular invasion, perineurial invasion, high Ki-67 labeling index, and low p19 expression. Importantly, BCL6 overexpression in GBC was strongly associated with worse DSS (pARF expression was correlated with a poor DSS (p=0.0144) and DFS (p=0.0032) in the univariate analysis but was not prognosticatory in the multivariate analysis. In GBC, BCL6 overexpression correlated with adverse phenotypes and decreased p19ARF expression. BCL6 overexpression also independently predicts worse DSS and DFS, suggesting it has a role in tumorigenesis or carcinogenesis and could be a potential prognostic indicator in GBC.

KW - BCL6

KW - Gallbladder carcinoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84898893269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898893269&partnerID=8YFLogxK

U2 - 10.1007/s13277-013-1195-z

DO - 10.1007/s13277-013-1195-z

M3 - Article

C2 - 24114011

AN - SCOPUS:84898893269

VL - 35

SP - 1417

EP - 1426

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 2

ER -